Checkpoint Therapeutics recently gained approval for cosibelimab, a PD-L1 inhibitor for advanced cSCC, but faces stiff competition and financial challenges. CKPT's pipeline includes cosibelimab, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results